Sullo & Sullo - Drug Litigation - Pradaxa Blog

RssIcon
Tuesday, June 19, 2012
This article will continue the discussion held by a group of attorneys during a recent Pradaxa litigation seminar. The discussion centered primarily around venue although cause of action and filing were also discussed. Boehringer’s primary American base is in Connecticut which is also the home of large numbers of insurance companies. This can lead to extremely tough jury pools and is something to consider when discussing alternative venues.
Sunday, June 17, 2012
Continuing from Part One of the Pradaxa Lawsuit articles, we continue with the discussion held by attorneys who are interested in Pradaxa litigation and the issues they found to be of primary importance. Discussed at length was the RE-LY study Boehringer Ingelheim used in order to receive FDA approval
Friday, June 15, 2012
A group of attorneys interested in the Pradaxa litigation assembled to discuss the issue in a recent seminar. Pradaxa is a drug prescribed primarily for atrial fibrillation, which is essentially an irregular heartbeat.
Thursday, June 14, 2012
As a continuing discussion of the science behind the medication Pradaxa, used in the treatment of atrial fibrillation, it is believed that the high incidence GI issues experienced in Pradaxa users relates directly to its unique delivery system. Pradaxa is absorbed most readily when low pH levels are present.
Wednesday, June 13, 2012
Pradaxa is a prescription drug manufactured by Boehringer Ingelheim which is most commonly prescribed for symptoms of atrial fibrillation. Atrial fibrillation is a condition in which the two upper chambers of the heart slowly begin to fail to rhythmically contract. These chambers then flutter in an irregular manner, which, in some cases, has little effect on the overall health of the patient other than a modest reduction in cardiac output.
Monday, June 11, 2012
Pradaxa is a drug which is a newcomer into the pharmaceutical marketplace, used in the treatment of atrial fibrillation and the subsequent prevention of strokes. The only drug of its kind, Warfarin, has been in use as an anticoagulant and to treat atrial fibrillation for over half a century—since 1957
Saturday, June 09, 2012
Approved by the FDA in October 2010, Pradaxa is the first anticoagulant drug to be marketed in over half a century. Warfarin was approved for use in 1957 and despite its limitations has been used ever since. Both drugs are used in the treatment of atrial fibrillation which can lead to stroke.
Tuesday, June 05, 2012
Boehringer Ingelheim announced in March of 2008 that the European Commission had granted approval to market their new oral thrombin inhibitor known as Pradaxa 27 EU states. At this juncture it was expected that Pradaxa would soon be released in Germany and the UK as well.
Sunday, April 15, 2012
If your doctor has prescribed the relatively new drug, Pradaxa, as an alternative to Warfarin, you may have been alarmed to hear of the potential issues with Pradaxa. Pradaxa was approved by the FDA in late 2010 after the manufacturer, Boehringer Ingelheim, presented the drug as a much better alternative to Warfarin.
Saturday, March 31, 2012
Pradaxa, the drug which less than a couple of years ago seemed like a dream come true for the hundreds of thousands of patients who were taking Warfarin or Coumadin has had its initial glow tarnished by the ever-increasing number of reports of serious side effects from use of the drug. Although Warfarin has been used as a stroke inhibitor and for those suffering from atrial fibrillation since the 1950’s, it comes with certain restrictions and its own set of side effects.
Friday, March 30, 2012
Some experts feel that the German pharmaceutical company, Boehringer Ingelheim, rushed their new wonder drug, Pradaxa to the market perhaps a bit too quickly in an attempt to beat the competitors to the mark. Pradaxa subsequently became the first drug to rival Warfarin in over half a century.
Thursday, March 29, 2012
March of 2012 saw the first lawsuits filed against Boehringer Ingelheim, the manufacturer of Pradaxa. This drug was the first of its type to be marketed in over half a century, and Boehringer had high hopes that Pradaxa would knock its only competitor, Warfarin, out of the running in short order.
Wednesday, March 28, 2012
The newest drug approved for use in the treatment of heart valve problems or atrial fibrillation among patients with an increased risk of stroke is the drug Pradaxa, manufactured by Boehringer Ingelheim. The drug Boehringer is seeking to replace with its newest arrival is Warfarin—a blood-thinning drug which has been used since the early 1950’s.
Tuesday, March 27, 2012
Although only on the market for a relatively short period of time, Pradaxa, the blood-thinning drug manufactured by Boehringer Ingelheim—has already suffered under the weight of threatened recalls, lawsuits and warnings by the FDA. Pradaxa is the first FDA-approved drug of its type since the drug Warfarin was approved in 1954.

Free Consultation
Receive an immediate response to your request.
Choose the Practice Area of Your Problem:

I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared. I further understand and agree to the Terms of Use and Privacy Policy

CAPTCHA image
Enter the code shown above in the box below

Get Interactive

Sullo & Sullo-Facebook Sullo & Sullo-Linkedin Sullo & Sullo-Twitter Sullo & Sullo-You Tube
 

Recent Articles & Publications

June 19, 2012
This article will continue the discussion held by a group of attorneys during a recent Pradaxa litigation seminar. The discussion centered primarily around venue although...

June 17, 2012
Continuing from Part One of the Pradaxa Lawsuit articles, we continue with the discussion held by attorneys who are interested in Pradaxa litigation and the issues they found...

June 15, 2012
A group of attorneys interested in the Pradaxa litigation assembled to discuss the issue in a recent seminar. Pradaxa is a drug prescribed primarily for atrial fibrillation,...